Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: A multicentre, randomized, double-blind, placebo-controlled study

International Journal of Neuropsychopharmacology

Volumn 13, Issue 7, 2010, Pages 917-932

  El Khalili, Nizar ^a   Joyce, Mark ^b   Atkinson, Sarah ^c   Buynak, Robert J ^d   Datto, Catherine ^e   Lindgren, Petter ^f   Eriksson, Hans ^f  

^a Alpine Clinic   (United States)

^b CNS Healthcare   (United States)

^c Finger Lakes Clinical Research   (United States)

^d Northwest Indiana Center for Clinical Research   (United States)

^e ASTRAZENECA   (United Kingdom)

^f ASTRAZENECA R AND D   (Sweden)

Author keywords

Adjunctive therapy; atypical antipsychotic; depression; extended release quetiapine fumarate; ongoing antidepressant

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; PAROXETINE; PLACEBO; QUETIAPINE; SERTRALINE; VENLAFAXINE;

ADJUVANT THERAPY; ADULT; AGED; AKATHISIA; ARTICLE; CERVICAL SPONDYLOSIS; CHILL; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG RELEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYNDROME; FATIGUE; FEMALE; FOLLOW UP; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HEADACHE; HUMAN; HYPERSALIVATION; HYPERSOMNIA; INCREASED APPETITE; INSOMNIA; IRRITABILITY; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; MUSCLE HYPERTONIA; MUSCLE RIGIDITY; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RESTLESSNESS; SCORING SYSTEM; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SUICIDE; SWEATING; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; WEIGHT; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77956440952     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145710000015     Document Type: Article

References (42)

1. AstraZeneca (2008). Seroquel1 (quetiapine fumarate) tablets/US prescribing information (http:// www1.astrazeneca-us.com/pi/seroquel.pdf).
2. Barbee JG, Conrad EJ, Jamhour NJ (2004). The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. Journal of Clinical Psychiatry 65, 975-981.
3. Barnes TR (1989). A rating scale for drug-induced akathisia. British Journal of Psychiatry 154, 672-676.
4. Bauer M, Bschor T, Pfennig A, Whybrow PC, et al. (2007). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World Journal of Biological Psychiatry 8, 67-104. (Pubitemid 46690921)
5. Bauer M, Pretorius H, Constant E, Earley W, et al. (2009). Extended release quetiapine fumarate as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. Journal of Clinical Psychiatry 70, 540-549.
6. Berman RM, Fava M, Thase ME, Trivedi MH, et al. (2009). Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectrums 14, 197-206.
7. Berman RM, Marcus RN, Swanink R, McQuade RD, et al. (2007). The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry 68, 843-853. (Pubitemid 47015482)
8. Buckley PF (2004). Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials. Current Medical Research and Opinion 20, 1357-1363.
9. Calabrese JR, Keck PE, Macfadden W, Minkwitz M, et al. (2005). A randomized, double-blind, placebocontrolled trial of quetiapine in the treatment of bipolar I or II depression. American Journal of Psychiatry 162, 1351-1360. (Pubitemid 40905587)
10. Casey DE (2006). Implications of the CATIE trial on treatment: extrapyramidal symptoms. CNS Spectrums 11, 25-31. (Pubitemid 44141226)
11. Crown WH, Finkelstein S, Berndt ER, Ling D, et al. (2002). The impact of treatment-resistant depression on health care utilization and costs. Journal of Clinical Psychiatry 63, 963-971. (Pubitemid 35388053)
12. Cutler A, Montgomery S, Feifel D, Lazarus A, et al. (2009). Extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. Journal of Clinical Psychiatry 70, 526-539.
13. Datto C, Lam RW, Lepola U, Sweitzer D, et al. (2008). Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment in patients with MDD. European Neuropsychopharmacology 18 (Suppl. 4), S377.
14. El-Khalili N, Banov M, Bortnick B, Adson D, et al. (2009). Extended release quetiapine fumarate (quetiapine XR) monotherapy for the treatment of patients with major depressive disorder (MDD): a randomized, placebocontrolled clinical trial. World Journal of Biological Psychiatry 10 (Suppl. 1), 230.
15. Endicott J, Nee J, Harrison W, Blumenthal R (1993). Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacology Bulletin 29, 321-326. (Pubitemid 23311543)
16. Goldstein JM, Nyberg S, Brecher M (2008). Preclinical mechanisms for the broad spectrum of antipsychotic, antidepressant and mood stabilizing properties of Seroquel. European Psychiatry 23 (Suppl. 2), S202.
17. Hamilton M (1959). The assessment of anxiety states by rating. British Journal of Medical Psychology 32, 50-55.
18. Hasin DS, Goodwin RD, Stinson FS, Grant BF (2005). Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Archives of General Psychiatry 62, 1097-1106. (Pubitemid 41396935)
19. Hirschfeld RM,Montgomery SA, Aguglia E, Amore M, et al. (2002). Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. Journal of Clinical Psychiatry 63, 826-837.
20. Hommel G (1988). A stagewise rejective multiple test procedure based on a modified Bonferroni test. Biometrika 75, 383-386.
21. Jensen NH, Rodriguiz RM, Caron MG, Wetsel WC, et al. (2008). N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT(1A) agonist, as a putative mediator of quetiapines antidepressant activity. Neuropsychopharmacology 33, 2303-2312.
22. Katila H, Mezhebovsky I, Mulroy A, Berggren L, et al. (2008). Efficacy and tolerability of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder (MDD). International Journal of Psychiatry in Clinical Practice 12, 337.
23. Kennedy SH, Lam RW, Cohen NL, Ravindran AV (2001). Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments. Canadian Journal of Psychiatry 46 (Suppl. 1), 38S-58S.
24. Mahmoud RA, Pandina GJ, Turkoz I, Kosik-Gonzalez C, et al. (2007). Risperidone for treatment-refractory major depressive disorder: a randomized trial. Annals of Internal Medicine 147, 593-602. (Pubitemid 351664478)
25. Marcus RN, McQuade RD, Carson WH, Hennicken D, et al. (2008). The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology 28, 156-165. (Pubitemid 351417120)
26. Masand PS (2003). Tolerability and adherence issues in antidepressant therapy. Clinical Therapeutics 25, 2289-2304.
27. McIntyre A, Gendron A, McIntyre A (2007). Quetiapine adjunct to selective serotonin reuptake inhibitors (SSRIs) or venlafaxine in patients with major depression, comorbid anxiety and residual depressive symptoms: a randomized, placebo controlled pilot study. Depression and Anxiety 24, 487-494. (Pubitemid 350086262)
28. Michelson D, Fava M, Amsterdam J, Apter J, et al. (2000). Interruption of selective serotonin reuptake inhibitor treatment. Double-blind, placebo-controlled trial. British Journal of Psychiatry 176, 363-368. (Pubitemid 30204663)
29. Montgomery SA, Åsberg M (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134, 382-389.
30. National Institutes of Mental Health (1970). CGI: clinical global impressions. In: Guy W, Bonato RR (Eds), Manual for the ECDEU Assessment Battery (pp. 1-6). Chevy Chase: NIMH.
31. Nemeroff CB (2007). Prevalence and management of treatment-resistant depression. Journal of Clinical Psychiatry 68 (Suppl. 8), 17-25.
32. Nyberg S, Takano A, Jucaite A, Karlsson P, et al. (2008). PET-measured occupancy of the NET by extended release quetiapine fumarate (quetiapine XR) in brains of healthy subjects. European Neuropsychopharmacology 18, S270.
33. Posner K, Oquendo MA, Gould M, Stanley B, et al. (2007). Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDAs pediatric suicidal risk analysis of antidepressants. American Journal of Psychiatry 164, 1035-1043. (Pubitemid 47121392)
34. Prince M, Patel V, Saxena S, Maj M, et al. (2007). No health without mental health. Lancet 370, 859-877. (Pubitemid 47371145)
35. Shelton RC, Williamson DJ, Corya SA, Sanger TM, et al. (2005). Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. Journal of Clinical Psychiatry 66, 1289-1297.
36. Simpson GM, Angus JWS (1970). A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica (Suppl.) 212, 11-19.
37. Souery D, Oswald P, Massat I, Bailer U, et al. (2007). Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. Journal of Clinical Psychiatry 68, 1062-1070. (Pubitemid 47340327)
38. Thase ME, Corya SA, Osuntokun O, Case M, et al. (2007). A randomized, double-blind comparison of olanzapine/ fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. Journal of Clinical Psychiatry 68, 224-236. (Pubitemid 46362643)
39. Thase ME, Macfadden W, Weisler RH, Chang W, et al. (2006). Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). Journal of Clinical Psychopharmacology 26, 600-609. (Pubitemid 44772737)
40. Trivedi MH (2006). Major depressive disorder: remission of associated symptoms. Journal of Clinical Psychiatry 67 (Suppl. 6), 27-32. (Pubitemid 44078110)
41. Weisler RH, Joyce M, McGill L, Lazarus A, et al. (2009). Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo controlled study. CNS Spectrums 14, 299-313.
42. Yargic LI, Corapcioglu A, Kocabasoglu N, Erdogan A, et al. (2004). A prospective randomized single-blind, multicenter trial comparing the efficacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety. International Journal of Psychiatry in Clinical Practice 8, 205-211. (Pubitemid 39611918)